Cargando…

Ultrastructural changes of erythrocytes in whole blood after exposure to prospective in silico-designed anticancer agents: a qualitative case study

BACKGROUND: Novel, in silico-designed anticancer compounds were synthesized in our laboratory namely, 2-ethyl-3-O-sulphamoyl-estra-1,3,5(10),15-tetraen-17-ol (ESE-15-ol) and 2-ethyl-3-O-sulphamoyl-estra-1,3,5(10)16-tetraene (ESE-16). These compounds were designed to have improved bioavailability whe...

Descripción completa

Detalles Bibliográficos
Autores principales: Repsold, Lisa, Mqoco, Thandi, Wolmarans, Elize, Nkandeu, Sandra, Theron, Joji, Piorkowski, Tomek, du Toit, Peet, van Papendorp, Dirk, Joubert, Annie Margaretha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4167501/
https://www.ncbi.nlm.nih.gov/pubmed/25299962
http://dx.doi.org/10.1186/0717-6287-47-39
_version_ 1782335428886528000
author Repsold, Lisa
Mqoco, Thandi
Wolmarans, Elize
Nkandeu, Sandra
Theron, Joji
Piorkowski, Tomek
du Toit, Peet
van Papendorp, Dirk
Joubert, Annie Margaretha
author_facet Repsold, Lisa
Mqoco, Thandi
Wolmarans, Elize
Nkandeu, Sandra
Theron, Joji
Piorkowski, Tomek
du Toit, Peet
van Papendorp, Dirk
Joubert, Annie Margaretha
author_sort Repsold, Lisa
collection PubMed
description BACKGROUND: Novel, in silico-designed anticancer compounds were synthesized in our laboratory namely, 2-ethyl-3-O-sulphamoyl-estra-1,3,5(10),15-tetraen-17-ol (ESE-15-ol) and 2-ethyl-3-O-sulphamoyl-estra-1,3,5(10)16-tetraene (ESE-16). These compounds were designed to have improved bioavailability when compared to their source compound, 2-methoxyestradiol. This theoretically would be due to their increased binding affinity to carbonic anhydrase II, present in erythrocytes. Since the novel compounds under investigation are proposed to be transported within erythrocytes bound to carbonic anhydrase II, the morphological effect which they may exert on whole blood and erythrocytes is of great significance. A secondary outcome included revision of previously reported procedures for the handling of the whole blood sample. The purpose of this study was twofold. Firstly, the ultrastructural morphology of a healthy female’s erythrocytes was examined via scanning electron microscopy (SEM) after exposure to the newly in silico-designed compounds. Morphology of erythrocytes following exposure to ESE-15-ol and ESE-16 for 3 minutes and 24 hours at 22°C were described with the use of SEM. The haemolytic activity of the compounds after 24 hours exposure were also determined with the ex vivo haemolysis assay. Secondly, storage conditions of the whole blood sample were investigated by determining morphological changes after a 24 hour storage period at 22°C and 37°C. RESULTS: No significant morphological changes were observed in the erythrocyte morphology after exposure to the novel anticancer compounds. Storage of the whole blood samples at 37°C for 24 hours resulted in visible morphological stress in the erythrocytes. Erythrocytes incubated at 22°C for 24 hours showed no structural deformity or distress. CONCLUSIONS: From this research the optimal temperature for ex vivo exposure of whole blood samples to ESE-15-ol and ESE-16 for 24 hours was determined to be 22°C. Data from this study revealed the potential of these compounds to be applied to ex vivo study techniques, since no damage occurred to erythrocytes ultrastructure under these conditions. As no structural changes were observed in erythrocytes exposed to ESE-15-ol and ESE-16, further ex vivo experiments will be conducted into the potential effects of these compounds on whole blood. Optimal incubation conditions up to 24 hours for whole blood were established as a secondary outcome.
format Online
Article
Text
id pubmed-4167501
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-41675012014-09-19 Ultrastructural changes of erythrocytes in whole blood after exposure to prospective in silico-designed anticancer agents: a qualitative case study Repsold, Lisa Mqoco, Thandi Wolmarans, Elize Nkandeu, Sandra Theron, Joji Piorkowski, Tomek du Toit, Peet van Papendorp, Dirk Joubert, Annie Margaretha Biol Res Research Article BACKGROUND: Novel, in silico-designed anticancer compounds were synthesized in our laboratory namely, 2-ethyl-3-O-sulphamoyl-estra-1,3,5(10),15-tetraen-17-ol (ESE-15-ol) and 2-ethyl-3-O-sulphamoyl-estra-1,3,5(10)16-tetraene (ESE-16). These compounds were designed to have improved bioavailability when compared to their source compound, 2-methoxyestradiol. This theoretically would be due to their increased binding affinity to carbonic anhydrase II, present in erythrocytes. Since the novel compounds under investigation are proposed to be transported within erythrocytes bound to carbonic anhydrase II, the morphological effect which they may exert on whole blood and erythrocytes is of great significance. A secondary outcome included revision of previously reported procedures for the handling of the whole blood sample. The purpose of this study was twofold. Firstly, the ultrastructural morphology of a healthy female’s erythrocytes was examined via scanning electron microscopy (SEM) after exposure to the newly in silico-designed compounds. Morphology of erythrocytes following exposure to ESE-15-ol and ESE-16 for 3 minutes and 24 hours at 22°C were described with the use of SEM. The haemolytic activity of the compounds after 24 hours exposure were also determined with the ex vivo haemolysis assay. Secondly, storage conditions of the whole blood sample were investigated by determining morphological changes after a 24 hour storage period at 22°C and 37°C. RESULTS: No significant morphological changes were observed in the erythrocyte morphology after exposure to the novel anticancer compounds. Storage of the whole blood samples at 37°C for 24 hours resulted in visible morphological stress in the erythrocytes. Erythrocytes incubated at 22°C for 24 hours showed no structural deformity or distress. CONCLUSIONS: From this research the optimal temperature for ex vivo exposure of whole blood samples to ESE-15-ol and ESE-16 for 24 hours was determined to be 22°C. Data from this study revealed the potential of these compounds to be applied to ex vivo study techniques, since no damage occurred to erythrocytes ultrastructure under these conditions. As no structural changes were observed in erythrocytes exposed to ESE-15-ol and ESE-16, further ex vivo experiments will be conducted into the potential effects of these compounds on whole blood. Optimal incubation conditions up to 24 hours for whole blood were established as a secondary outcome. BioMed Central 2014-09-04 /pmc/articles/PMC4167501/ /pubmed/25299962 http://dx.doi.org/10.1186/0717-6287-47-39 Text en © Repsold et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Repsold, Lisa
Mqoco, Thandi
Wolmarans, Elize
Nkandeu, Sandra
Theron, Joji
Piorkowski, Tomek
du Toit, Peet
van Papendorp, Dirk
Joubert, Annie Margaretha
Ultrastructural changes of erythrocytes in whole blood after exposure to prospective in silico-designed anticancer agents: a qualitative case study
title Ultrastructural changes of erythrocytes in whole blood after exposure to prospective in silico-designed anticancer agents: a qualitative case study
title_full Ultrastructural changes of erythrocytes in whole blood after exposure to prospective in silico-designed anticancer agents: a qualitative case study
title_fullStr Ultrastructural changes of erythrocytes in whole blood after exposure to prospective in silico-designed anticancer agents: a qualitative case study
title_full_unstemmed Ultrastructural changes of erythrocytes in whole blood after exposure to prospective in silico-designed anticancer agents: a qualitative case study
title_short Ultrastructural changes of erythrocytes in whole blood after exposure to prospective in silico-designed anticancer agents: a qualitative case study
title_sort ultrastructural changes of erythrocytes in whole blood after exposure to prospective in silico-designed anticancer agents: a qualitative case study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4167501/
https://www.ncbi.nlm.nih.gov/pubmed/25299962
http://dx.doi.org/10.1186/0717-6287-47-39
work_keys_str_mv AT repsoldlisa ultrastructuralchangesoferythrocytesinwholebloodafterexposuretoprospectiveinsilicodesignedanticanceragentsaqualitativecasestudy
AT mqocothandi ultrastructuralchangesoferythrocytesinwholebloodafterexposuretoprospectiveinsilicodesignedanticanceragentsaqualitativecasestudy
AT wolmaranselize ultrastructuralchangesoferythrocytesinwholebloodafterexposuretoprospectiveinsilicodesignedanticanceragentsaqualitativecasestudy
AT nkandeusandra ultrastructuralchangesoferythrocytesinwholebloodafterexposuretoprospectiveinsilicodesignedanticanceragentsaqualitativecasestudy
AT theronjoji ultrastructuralchangesoferythrocytesinwholebloodafterexposuretoprospectiveinsilicodesignedanticanceragentsaqualitativecasestudy
AT piorkowskitomek ultrastructuralchangesoferythrocytesinwholebloodafterexposuretoprospectiveinsilicodesignedanticanceragentsaqualitativecasestudy
AT dutoitpeet ultrastructuralchangesoferythrocytesinwholebloodafterexposuretoprospectiveinsilicodesignedanticanceragentsaqualitativecasestudy
AT vanpapendorpdirk ultrastructuralchangesoferythrocytesinwholebloodafterexposuretoprospectiveinsilicodesignedanticanceragentsaqualitativecasestudy
AT joubertanniemargaretha ultrastructuralchangesoferythrocytesinwholebloodafterexposuretoprospectiveinsilicodesignedanticanceragentsaqualitativecasestudy